At Hazeon Catalyst, we help investors, founders, and tech transfer offices evaluate early-stage oncology innovation.

We specialize in identifying and analyzing unlicensed academic IP as well as newly formed startups, assessing scientific validity, commercial potential, and strategic fit. Our team brings deep domain expertise to support due diligence, interrogate preclinical data, and ask the tough questions others miss.

Whether you’re vetting a new opportunity, preparing for a spinout, or deciding what to license next, we provide clear, science-driven analysis to help you move with confidence.